Alfasigma's PBC treatment Ocaliva to face an FDA adcomm in September
Italian pharma Alfasigma will face an FDA advisory committee next month to discuss the full approval of its rare liver disease treatment Ocaliva, a drug …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
